D-Index & Metrics Best Publications

Nils Brünner

University of Copenhagen
Denmark

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 84 Citations 22,587 472 World Ranking 10138 National Ranking 112

Overview

What is he best known for?

The fields of study Nils Brünner is best known for:

Gene
Antibody
Cancer

Nils Brünner undertakes interdisciplinary study in the fields of Receptor and Biochemistry through his research. He conducts interdisciplinary study in the fields of Biochemistry and Molecular biology through his research. Many of his studies on Molecular biology apply to Ligation as well. His work often combines Ligation and Polymerase chain reaction studies. He merges Polymerase chain reaction with Amplicon in his study. He performs multidisciplinary studies into Amplicon and Multiplex ligation-dependent probe amplification in his work. His Multiplex ligation-dependent probe amplification study typically links adjacent topics like Exon. Nils Brünner performs multidisciplinary studies into Exon and Gene in his work. Nils Brünner integrates several fields in his works, including Gene and Computational biology.

His most cited work include:

Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. (160 citations)
Multiplexed Homogeneous Proximity Ligation Assays for High-throughput Protein Biomarker Research in Serological Material (77 citations)

What are the main themes of his work throughout his whole career to date

Nils Brünner performs integrative study on Cancer and Cell growth in his works. In his works, Nils Brünner undertakes multidisciplinary study on Cell growth and Cancer. In most of his Internal medicine studies, his work intersects topics such as Transplantation. Nils Brünner connects Cancer research with Carcinogenesis in his study. Nils Brünner integrates many fields in his works, including Carcinogenesis and Cancer research. Borrowing concepts from Metastatic breast cancer, he weaves in ideas under Breast cancer. Nils Brünner conducts interdisciplinary study in the fields of Metastatic breast cancer and Breast cancer through his research. His Endocrinology study frequently draws connections to other fields, such as Plasminogen activator. In his study, he carries out multidisciplinary Plasminogen activator and Plasminogen activator inhibitor-1 research.

Nils Brünner most often published in these fields:

Cancer (76.92%)
Internal medicine (69.23%)
Cancer research (61.54%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization

Khalid Bajou;Agnès Noël;R. D. Gerard;Véronique Masson.
Nature Medicine (1998)

859 Citations

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck.
Journal of the National Cancer Institute (2002)

753 Citations

Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer

Jun Yu;Qiang Feng;Sunny Hei Wong;Dongya Zhang.
Gut (2017)

682 Citations

The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients

J. A. Foekens;H. A. Peters;M. P. Look;H. Portengen.
Cancer Research (2000)

561 Citations

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

Jan Grøndahl-Hansen;Ib Jarle Christensen;Christian Rosenquist;Nils Brünner.
Cancer Research (1993)

512 Citations

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Catharine M. Sturgeon;Michael J. Duffy;Ulf Håkan Stenman;Hans Lilja.
Clinical Chemistry (2008)

491 Citations

Prognostic Impact of Urokinase, Urokinase Receptor, and Type 1 Plasminogen Activator Inhibitor in Squamous and Large Cell Lung Cancer Tissue

Helle Pedersen;Nils Brünner;Dorthe Francis;Kell Østerlind.
Cancer Research (1994)

429 Citations

The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies

Khalid Bajou;Véronique Masson;Robert D. Gerard;Petra M. Schmitt.
Journal of Cell Biology (2001)

406 Citations

Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis

Ross W. Stephens;Hans Jørgen Nielsen;Ib J. Christensen;Ole Thorlacius-Ussing.
Journal of the National Cancer Institute (1999)

356 Citations

The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion

K. Danø;N. Behrendt;N. Brunner;V. Ellis.
Fibrinolysis and Proteolysis (1994)

355 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Nils Brünner